Pathophysiology of the metabolic syndrome

Clinics in Dermatology

Volumn 36, Issue 1, 2018, Pages 14-20

  McCracken, Emma ^a   Monaghan, Monica ^a   Sreenivasan, Shiva ^a,b  

^a Erne Hospital   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ARTICLE; ATHEROGENESIS; CHRONIC KIDNEY FAILURE; CORONARY ARTERY ATHEROSCLEROSIS; CYTOKINE RESPONSE; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSLIPIDEMIA; EXERCISE; GLUCOSE BLOOD LEVEL; GOUT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; INSULIN RESISTANCE; LICHEN PLANUS; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSORIASIS; RISK FACTOR; SLEEP DISORDERED BREATHING; SUPPURATIVE HIDRADENITIS; COMPLICATION; INFLAMMATION; METABOLISM;

CYTOKINES; HUMANS; INFLAMMATION; INSULIN RESISTANCE; METABOLIC SYNDROME; OBESITY, ABDOMINAL; OXIDATIVE STRESS;

EID: 85037670705     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2017.09.004     Document Type: Article

References (54)

1. Reaven, G.M., Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37 (1988), 1595–1607.
2. Alberti, K.G., Zimmet, P.Z., Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15 (1998), 539–553.
3. Balkau, B., Charles, M.A., Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 16 (1999), 442–443.
4. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 285, 2001, 2486–2497.
5. Einhorn, D., Reaven, G.M., Cobin, R.H., et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 9 (2003), 237–252.
6. Alberti, K.G., Zimmet, P., Shaw, J., The metabolic syndrome—a new worldwide definition. Lancet 366 (2005), 1059–1062.
7. Grundy, S.M., Cleeman, J.I., Daniels, S.R., et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005), 2735–2752.
8. Alberti, K.G., Eckel, R.H., Grundy, S.M., et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention;National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120 (2009), 1640–1645.
9. Aguilar, M., Bhuket, T., Torres, S., et al. Prevalence of the metabolic syndrome in the United States, 2003-2012. JAMA 313 (2015), 1973–1974.
10. Beltrán-Sánchez, H., Harhay, M.O., Harhay, M.M., et al. Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999-2010. J Am Coll Cardiol 62 (2013), 697–703.
11. Gao, W., Does the constellation of risk factors with and without abdominal adiposity associate with different cardiovascular mortality risk?. Int J Obes (Lond) 32 (2008), 757–762.
12. Mabry, R.M., Reeves, M.M., Eakin, E.G., et al. Gender differences in prevalence of the metabolic syndrome in Gulf Cooperation Council Countries: A systematic review. Diabet Med 27 (2010), 593–597.
13. Liu, M., Wang, J., Jiang, B., et al. Increasing prevalence of metabolic syndrome in a Chinese elderly population: 2001-2010. PLoS One, 8, 2013, e66233.
14. Lipińska, A., Koczaj-Bremer, M., Jankowski, K., et al. Does family history of metabolic syndrome affect the metabolic profile phenotype in young healthy individuals?. Diabetol Metab Syndr, 6, 2014, 75.
15. Sun, K., Liu, J., Ning, G., Active smoking and risk of metabolic syndrome: A meta-analysis of prospective studies. PLoS One, 7, 2012, e47791.
16. Park, Y.W., Zhu, S., Palaniappan, L., et al. The metabolic syndrome: Prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 163 (2003), 427–436.
17. Gennuso, K.P., Gangnon, R.E., Thraen-Borowski, K.M., et al. Dose-response relationships between sedentary behaviour and the metabolic syndrome and its components. Diabetologia 58 (2015), 485–492.
18. Dhingra, R., Sullivan, L., Jacques, P.F., et al. Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community. Circulation 116 (2007), 480–488.
19. Green, A.K., Jacques, P.F., Rogers, G., et al. Sugar-sweetened beverages and prevalence of the metabolically abnormal phenotype in the Framingham Heart Study. Obesity (Silver Spring) 22 (2014), e157–163.
20. Fan, A.Z., Russell, M., Naimi, T., et al. Patterns of alcohol consumption and the metabolic syndrome. J Clin Endocrinol Metab 93 (2008), 3833–3838.
21. Lutsey, P.L., Steffen, L.M., Stevens, J., Dietary intake and the development of the metabolic syndrome: The Atherosclerosis Risk in Communities study. Circulation 117 (2008), 754–761.
22. LaMonte, M.J., Barlow, C.E., Jurca, R., et al. Cardiorespiratory fitness is inversely associated with the incidence of metabolic syndrome: A prospective study of men and women. Circulation 112 (2005), 505–512.
23. Chang, P.C., Li, T.C., Wu, M.T., et al. Association between television viewing and the risk of metabolic syndrome in a community-based population. BMC Public Health, 8, 2008, 193.
24. Freitas, P., Carvalho, D., Souto, S., et al. Impact of lipodystrophy on the prevalence and components of metabolic syndrome in HIV-infected patients. BMC Infect Dis, 11, 2011, 246.
25. Lamberti, J.S., Olson, D., Crilly, J.F., et al. Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 163 (2006), 1273–1276.
26. Eckel, R.H., Grundy, S.M., Zimmet, P.Z., The metabolic syndrome. Lancet 365 (2005), 1415–1428.
27. Roberts, C.K., Hevener, A.L., Barnard, R.J., Metabolic syndrome and insulin resistance: Underlying causes and modification by exercise training. Compr Physiol 3 (2013), 1–58.
28. Saltiel, A.R., Kahn, C.R., Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414 (2001), 799–806.
29. Lizcano, J.M., Alessi, D.R., The insulin signalling pathway. Curr Biol 12 (2002), R236–238.
30. Choi, S.M., Tucker, D.F., Gross, D.N., et al. Insulin regulates adipocyte lipolysis via an Akt-independent signaling pathway. Mol Cell Biol 30 (2010), 5009–5020.
31. Bryant, N.J., Govers, R., James, D.E., Regulated transport of the glucose transporter GLUT4. Nat Rev Mol Cell Biol 3 (2002), 267–277.
32. Savage, D.B., Petersen, K.F., Shulman, G.I., Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev 87 (2007), 507–520.
33. Kim, D.H., Perdomo, G., Zhang, T., et al. FoxO6 integrates insulin signaling with gluconeogenesis in the liver. Diabetes 60 (2011), 2763–2774.
34. Dentin, R., Liu, Y., Koo, S.H., et al. Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2. Nature 449 (2007), 366–369.
35. Li, X., Monks, B., Ge, Q., et al. Akt/PKB regulates hepatic metabolism by directly inhibiting PGC-1alpha transcription coactivator. Nature 447 (2007), 1012–1016.
36. DeFronzo, R.A., Ferrannini, E., Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14 (1991), 173–194.
37. Jensen, M.D., Caruso, M., Heiling, V., et al. Insulin regulation of lipolysis in nondiabetic and IDDM subjects. Diabetes 38 (1989), 1595–1601.
38. Ford, E.S., The metabolic syndrome and mortality from cardiovascular disease and all-causes: Findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 173 (2004), 309–314.
39. Ryo, M., Nakamura, T., Kihara, S., et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 68 (2004), 975–981.
40. Lau, D.C., Dhillon, B., Yan, H., et al. Adipokines: Molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol 288 (2005), H2031–2041.
41. Halberg, N., Wernstedt-Asterholm, I., Scherer, P.E., The adipocyte as an endocrine cell. Endocrinol Metab Clin North Am 37 (2008), 753–768 x-xi.
42. Cinti, S., Mitchell, G., Barbatelli, G., et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 46 (2005), 2347–2355.
43. Kaur, J., A comprehensive review on metabolic syndrome. Cardiol Res Pract, 2014, 2014, 943162.
44. Testa, R., Olivieri, F., Bonfigli, A.R., et al. Interleukin-6-174 G > C polymorphism affects the association between IL-6 plasma levels and insulin resistance in type 2 diabetic patients. Diabetes Res Clin Pract 71 (2006), 299–305.
45. Bao, P., Liu, G., Wei, Y., Association between IL-6 and related risk factors of metabolic syndrome and cardiovascular disease in young rats. Int J Clin Exp Med 8 (2015), 13491–13499.
46. Bernberg, E., Ulleryd, M.A., Johansson, M.E., et al. Social disruption stress increases IL-6 levels and accelerates atherosclerosis in ApoE-/- mice. Atherosclerosis 221 (2012), 359–365.
47. Kim, Y.D., Kim, Y.H., Cho, Y.M., et al. Metformin ameliorates IL-6-induced hepatic insulin resistance via induction of orphan nuclear receptor small heterodimer partner (SHP) in mouse models. Diabetologia 55 (2012), 1482–1494.
48. Azzawi, M., Hasleton, P., Tumour necrosis factor alpha and the cardiovascular system: Its role in cardiac allograft rejection and heart disease. Cardiovasc Res 43 (1999), 850–859.
49. Kerdel, F., Zaiac, M., An evolution in switching therapy for psoriasis patients who fail to meet treatment goals. Dermatol Ther 28 (2015), 390–403.
50. Alessi, M.C., Juhan-Vague, I., PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol 26 (2006), 2200–2207.
51. Furukawa, S., Fujita, T., Shimabukuro, M., et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114 (2004), 1752–1761.
52. Srikanthan, K., Feyh, A., Visweshwar, H., et al. Systematic review of metabolic syndrome biomarkers: A panel for early detection, management, and risk stratification in the West Virginian population. Int J Med Sci 13 (2016), 25–38.
53. Matsuzawa, Y., Funahashi, T., Kihara, S., et al. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 24 (2004), 29–33.
54. Landar, A., Zmijewski, J.W., Dickinson, D.A., et al. Interaction of electrophilic lipid oxidation products with mitochondria in endothelial cells and formation of reactive oxygen species. Am J Physiol Heart Circ Physiol 290 (2006), H1777–1787.